New drug IBI133 tested in patients with advanced cancers
NCT ID NCT06170190
First seen Nov 17, 2025 · Last updated May 01, 2026 · Updated 19 times
Summary
This early-phase trial tested a new drug called IBI133 in 19 adults with advanced solid tumors that could not be removed by surgery. The main goals were to find a safe dose and see if the drug can shrink tumors. The study is now complete, and results will help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Liverpool Hospital
Liverpool, New South Wales, 2170, Australia
Conditions
Explore the condition pages connected to this study.